Ox­ford spin­out grabs $9M A round for pep­tide plat­form; blue­bird gets a 'break­through' at the FDA

→ An Ox­ford spin­out has nabbed about $9 mil­lion in a Se­ries A round de­signed to al­low the uni­ver­si­ty founders to in­dus­tri­al­ize their pep­tide dis­cov­ery and de­vel­op­ment plat­form. Pro­fes­sors Gra­ham Ogg and Ter­ry Rab­bitts start­ed Or­bit Dis­cov­ery and say they al­ready have three phar­ma part­ners for the biotech up­start. Ox­ford Sci­ences In­no­va­tion led the round, joined by new in­vestors RT Ven­tures, Bo­re­alis Ven­tures, Periv­o­li In­no­va­tions, along with fur­ther in­vest­ment from all ex­ist­ing in­vestors and Ox­ford Uni­ver­si­ty. “We’ve been very suc­cess­ful in de­liv­er­ing on Or­bit’s strat­e­gy, lead­ing to growth in both ca­pa­bil­i­ty de­vel­op­ment and com­mer­cial col­lab­o­ra­tions,” com­ment­ed Alex Batch­e­lor, CEO at Or­bit. “This Se­ries A fund­ing al­lows us to great­ly ex­pand plat­form in­dus­tri­al­i­sa­tion whilst achiev­ing the mile­stones in our ex­ist­ing three phar­ma part­ner­ships. More­over, we can sup­port fur­ther strate­gic col­lab­o­ra­tions that align with de­vel­op­ment of our plat­form.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER